Instructions Mukaltin forte with vitamin C chewable tablets blister No. 20
Composition
active ingredients: 1 tablet contains mucaltin 100 mg, ascorbic acid 100 mg;
excipients: sucrose (sucrose), microcrystalline cellulose, sorbitol (E 420), aspartame (E 951), calcium stearate, flavoring (orange).
Dosage form
Chewable tablets.
Main physicochemical properties: tablets are grayish-brown in color with inclusions, round in shape with a biconvex surface, non-uniformity of the color of the tablet surfaces is allowed.
Pharmacotherapeutic group
Expectorants. ATX code R05C A05.
Pharmacological properties
Mukaltin® Forte with vitamin C is an expectorant, the action of which is due to secretolytic and bronchodilator properties. The drug has a moderate antitussive effect, reduces the number of coughing attacks and their intensity, increases the amount of sputum and reduces its viscosity. It has a softening, anti-inflammatory and enveloping effect. Normalizes altered bronchopulmonary secretion, improves sputum discharge.
Ascorbic acid (vitamin C) participates in redox reactions, metabolism of carbohydrates, tyrosine, iron, conversion of folic acid to folinic acid, blood clotting, formation of steroid hormones, collagen and procollagen, tissue regeneration, regulation of capillary permeability, synthesis of lipids and proteins, and processes of cellular respiration.
Vitamin C helps increase the body's resistance to infections and adverse environmental influences.
Indication
Cough in acute and chronic respiratory diseases accompanied by the formation of thick and viscous bronchial secretions and/or impaired expectoration: bronchitis, pneumonia, bronchiectasis, bronchial asthma.
Contraindication
Hypersensitivity to the components of the drug. Thrombosis, thrombophlebitis, diabetes mellitus, severe kidney disease. Phenylketonuria, congenital fructose intolerance, glucose-galactose malabsorption syndrome.
Interaction with other medicinal products and other types of interactions
Do not administer simultaneously with drugs that suppress cough (codeine).
Due to the presence of ascorbic acid in its composition, the drug reduces the toxicity of sulfonamide drugs, reduces the effect of heparin and indirect anticoagulants, promotes iron absorption, increases the absorption of penicillin and tetracycline, and enhances the side effect of salicylates (risk of crystalluria).
The use of oral contraceptives, drinking juices, and alkaline drinks reduces the level of vitamin C in the body.
Vitamin C in combination with deferoxamine increases tissue toxicity of iron, especially in the heart muscle, which can lead to decompensation of the circulatory system. Therefore, Mukaltin® Forte with vitamin C can be taken only 2 hours after the injection of deferoxamine.
Vitamin C increases the total clearance of ethyl alcohol.
If the recommended doses of Mukaltin® Forte with vitamin C are significantly exceeded, the drug may reduce the effectiveness of tricyclic antidepressants, neuroleptics - phenothiazine derivatives, tubular reabsorption of amphetamine, disrupt the excretion of mexiletine by the kidneys, and inhibit the disulfiram-alcohol reaction in people treated with disulfiram.
Application features
The drug may alter the results of various laboratory tests (blood glucose, bilirubin, transaminase activity, lactate dehydrogenase). Vitamin C absorption may be impaired in intestinal dyskinesias, enteritis, and achilia.
Large doses of the drug, significantly exceeding the recommended ones, due to the presence of vitamin C in the composition of the drug, should not be taken in cases of increased blood clotting, in patients with a history of kidney disease, hemochromatosis, thalassemia, polycythemia, or urolithiasis.
If shortness of breath, fever, or purulent sputum develops during treatment, you should consult a doctor immediately.
Sometimes in patients with chronic inflammatory lung diseases at the beginning of treatment with MukaltinÒ forte with vitamin C, sputum viscosity may increase due to the separation of sputum that has accumulated in the bronchial tree and contains a large amount of detritus, proteins and inflammatory elements. Therefore, in case of diffuse bronchial lesions, significant changes in the physicochemical properties of sputum and a decrease in mucociliary transport, therapy with MukaltinÒ forte with vitamin C should be combined with the appointment of mucolytic drugs.
Due to the presence of sucrose (sucrose) in the composition, the drug may have a harmful effect on teeth.
Use during pregnancy or breastfeeding
There is no experience of use.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Method of administration and doses
The usual course of treatment is 5-7 days. If symptoms persist after this course of treatment, you should consult your doctor about the possibility of extending the treatment period.
Children
The drug should not be prescribed to children under 3 years of age.
Overdose
When using the indicated therapeutic doses of the drug, overdose is impossible.
Overdose causes nausea, vomiting, heartburn, diarrhea, dizziness, increased excitability, sleep disturbances, headache, vitamin C hypervitaminosis, damage to the glomerular apparatus of the kidneys, crystalluria, formation of urate and oxalate stones; possible inhibition of the function of the insular apparatus of the pancreas, impaired glycogen synthesis up to the onset of diabetes mellitus, arterial hypertension, myocardial dystrophy, thrombocytosis, hyperprothrombinemia, erythrocytopenia, neutrophilic leukocytosis, impaired zinc and copper metabolism.
Treatment: gastric lavage and consult a doctor. Therapy is symptomatic.
Adverse reactions
In some cases, allergic reactions may occur, including rash, urticaria, itching of the skin, angioedema, and anaphylactic shock.
From the nervous system: headache.
On the part of the digestive tract: dyspeptic disorders, including heartburn, diarrhea, nausea, vomiting.
Blood and lymphatic system disorders: In patients with glucose-6-phosphate dehydrogenase deficiency, red blood cell hemolysis may occur.
Others: feeling hot.
If adverse reactions occur, it is necessary to discontinue use of the drug.
Expiration date
2 years.
Storage conditions
In the original packaging, at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
10 tablets in a blister, 2 or 10 blisters in a pack.
Vacation category
Without a prescription.
Producer
PJSC "Kyivmedpreparat".
Location of the manufacturer and its business address
Ukraine, 01032, Kyiv, Saksaganskoho St., 139.
Applicant
PJSC "Halychpharm".
Applicant's location
Ukraine, 79024, Lviv, Opryshkivska St., 6/8.
